Condition
Mesothelioma|Bladder Cancer|Melanoma|Squamous Cell Carcinoma of the Head and Neck|Non Small Cell Lung Cancer|Clear Cell Renal Cell Carcinoma|Ovarian Cancer|Thyroid Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer|Colon Cancer|Soft Tissue Sarcoma
Estimated Enrollment: 114
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: CP-MGD009-01
Study First Received: November 20, 2015
Last Updated: August 10, 2016
Estimated Primary Completion Date: December 2018
Primary Outcome Measures:
Number of participants with adverse events|Peak plasma concentration|Number of participants that develop anti-drug antibodies|Change in tumor volume
Sponsors and Collaborators:
MacroGenics
Website Link: https://ClinicalTrials.gov/show/NCT02628535
